Stock Movers: Meta, Ford, Eli Lilly (Podcast)

Meta shares fell after lifting full-year capex guidance to $125 billion-$145 billion and announcing a $20 billion-$25 billion bond sale to fund AI investment and higher component costs. Ford raised its full-year EBIT outlook to as much as $10.5 billion, but warned of a $2 billion profit hit from higher steel and aluminum costs; shares slipped. Eli Lilly advanced after boosting its sales and profit forecast, now seeing 2026 sales up to $85 billion and EPS of $35.50-$37, supported by obesity drug demand and its new weight-loss pill.

Analysis

Meta’s spending reset is less about one quarter of capex and more about a longer-dated repricing of free cash flow durability. The market is signaling that AI monetization remains too speculative relative to the pace of infrastructure burn, and the bond deal adds a second pressure point: equity now has to absorb both dilution-to-FCF skepticism and a more levered balance-sheet narrative. In the near term, the most vulnerable holders are growth/quality crowding names that trade off “platform optionality” rather than visible cash conversion.

Ford’s guide-up with a commodity headwind is a classic margin mix story: better trucks/SUVs can offset part of the input inflation, but the cost shock tells you the earnings ceiling is still constrained by exogenous metal prices. The second-order effect is that suppliers with pricing power and low fixed costs should hold up better than OEMs; the market may be underestimating how quickly a $2B commodity hit can bleed into inventory valuation and dealer incentives over the next 1-2 quarters. If steel/aluminum stay sticky, the equity upside from the raised outlook can get capped fast.

Eli Lilly is the cleanest fundamental beneficiary because obesity demand remains one of the few areas where pricing, volume, and product cadence are all moving in the same direction. The market may still be underappreciating how a successful oral weight-loss launch expands the addressable pool well beyond injectable adopters, which matters for penetration and payer negotiations over the next 12-24 months. The main risk is not demand saturation but capacity and reimbursement friction; any hiccup there would compress the premium multiple even if sell-through remains strong.

Key Decisions for Investors

• Short META into strength or buy 1-3 month put spreads: the trade is a FCF-quality reset, not a one-day reaction. Use a structure that wins if the market keeps discounting AI spend-to-revenue conversion over the next 4-8 weeks.
• Pair long LLY / short META for a 2-6 month horizon: this isolates the market’s preference for visible monetization over speculative infrastructure spend. Risk is a broad growth rally that lifts both, so keep sizing modest and rebalance on any AI capex stabilization signal.
• Fade F on rallies via call overwrites or short-dated put spreads: the commodity-cost overhang should be more visible in the next 1-2 earnings cycles than the guidance raise. Best entry is after any upgrade-driven pop that ignores input inflation.
• If you want a cleaner relative-value expression, go long LLY against a basket of mega-cap AI capex intensives. The premise is that capital allocation discipline will matter more than narrative momentum over the next quarter.
• Set a catalyst watch on commodity prints and supplier commentary for F over the next 30-60 days; if steel/aluminum stabilize, cover shorts quickly because the stock can rerate on margin resilience.